Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | GPR3 | P46089 | 1/20 | 0.46 |
| ▸ | DHFR | P00374 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29099832 | 0.98 | KMT2A (0.53) | KMT2ATLR8ATMSMN1; SMN2KDM4E | |
| SCHEMBL29539238 | 0.95 | KMT2A (0.56) | KMT2ATLR8ATMSMN1; SMN2KDM4E | |
| SCHEMBL2186187 | 0.87 | KDM4E (0.60) | KMT2ATLR8ATMSMN1; SMN2KDM4E | |
| SCHEMBL30277428 | 0.86 | TLR8 (0.46) | KMT2ATLR8ATMSMN1; SMN2KDM4E | |
| SCHEMBL13585880 | 0.83 | TLR8 (0.48) | TLR8ATMSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL19751006 | 0.83 | TLR8 (0.54) | TLR8ATMSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL8518275 | 0.83 | TLR8 (0.50) | TLR8ATMSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL6722631 | 0.81 | TLR8 (0.47) | TLR8ATMSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3792910 | 0.81 | DHFR (0.58) | TLR8ATMSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL27863633 | 0.81 | KCNH2 (0.53) | TLR8ATMSMN1; SMN2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116589407-A | Synthesis method of 6-aryl phenanthridine compound | 湖南科技学院 | 2023-08-15 | — | — | CN | claimed |
| CN-116969889-B | Preparation method of phenanthridine or chiral phenanthridine compound | 瑞博(杭州)医药科技有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-116969889-A | Preparation method of phenanthridine or chiral phenanthridine compound | 瑞博(杭州)医药科技有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-115385909-B | Method for synthesizing imidazophenanthridine compounds through palladium-copper co-catalysis | 江苏师范大学 | 2023-09-29 | — | — | CN | disclosed |
| CN-116589407-A | Synthesis method of 6-aryl phenanthridine compound | 湖南科技学院 | 2023-08-15 | — | — | CN | disclosed |
| CN-115385909-A | Method for synthesizing imidazophenanthridine compound under co-catalysis of palladium and copper | 江苏师范大学 | 2022-11-25 | — | — | CN | disclosed |
| CN-108314649-B | Synthetic method of 6-phenylphenanthridine compound | 温州大学 | 2021-03-19 | — | — | CN | disclosed |
| US-9962377-B2 | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | TAKEDA GMBH (DE) | 2018-05-08 | — | — | US | disclosed |
| US-20160279120-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | TAKEDA GMBH (DE) | 2016-09-29 | — | — | US | disclosed |
| US-9387205-B2 | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | TAKEDA GMBH (DE) | 2016-07-12 | — | — | US | disclosed |
| EP-1856093-A1 | NOVEL SALTS OF 6-HETEROCYCLYL SUBSTITUTED HEXAHYDROPHENANTHRIDINE DERIVATIVES | Nycomed GmbH (DE) | 2007-11-21 | — | — | EP | disclosed |
| EP-1736471-A1 | 3-(DIHYDRO(TETRAHYDRO)ISOQUINOLIN-1-YL)QUINOLINES | Sankyo Agro Company, Limited (JP) | 2006-12-27 | — | — | EP | disclosed |
| EP-1723135-A1 | NOVEL HYDROXY-6-HEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | Altana Pharma AG (DE) | 2006-11-22 | — | — | EP | disclosed |
| WO-2006092422-A1 | NOVEL SALTS OF 6-HETEROCYCLYL SUBSTITUTED HEXAHYDROPHENANTHRIDINE DERIVATIVES | NYCOMED GMBH (DE) | 2006-09-08 | — | — | WO | disclosed |
| EP-1147088-B1 | 6-ARYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY | ALTANA PHARMA AG (DE) | 2006-01-04 | — | — | EP | disclosed |
| WO-2005085225-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2005-09-15 | — | — | WO | disclosed |
| US-6479505-B1 | TREATING AIRWAY DISORDER IN A PATIENT COMPRISING ADMINISTERING TO SAID PATIENT IN NEED THEREOF A THERAPEUTICALLY EFFECTIVE AMOUNT OF A PHOSPHODIESTERASE IV INHIBITOR | ALTANA PHARMA AG (DE) | 2002-11-12 | — | — | US | disclosed |
| US-6479505-B1 | TREATING AIRWAY DISORDER IN A PATIENT COMPRISING ADMINISTERING TO SAID PATIENT IN NEED THEREOF A THERAPEUTICALLY EFFECTIVE AMOUNT OF A PHOSPHODIESTERASE IV INHIBITOR | ALTANA PHARMA AG (DE) | 2002-11-12 | — | — | US | disclosed |
| EP-1147088-A1 | 6-ARYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000042019-A1 | 6-ARYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160279120-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE12, PDE4B | KMT2A 750/4885TLR8 1472/4885ATM 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.